December 17th 2024
Clesrovimab, if approved, would be the only immunization for both healthy and at risk infants using the same dose. FDA set A PDUFA date of June 2025.
More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression
View More
Community Practice Connections™: Navigating a New Era of Food Allergy Management
View More
4th Annual International Congress on Pediatric Oncology
November 7, 2025
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts
View More
Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations
View More
Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy
View More
Medical Crossfire®: Optimal Approaches to Evaluating and Addressing Pain in the Patient With Sickle Cell Disease
View More
Clinical Case Vignette Series™: 3rd Annual International Congress on Pediatric Oncology
View More
Evolving Treatment Paradigms for Patients With Hemoglobinopathies
View More